IOL Chemicals & Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, through a regulatory filing on February 11, 2026. The Board of Directors approved the results at their meeting held on the same day, which commenced at 1:15 PM and concluded at 2:31 PM.

Q3 FY26 Financial Performance

The company reported steady financial performance for the quarter ended December 31, 2025. The standalone financial results showed consistent operational metrics across key parameters.

Nine Months Performance

For the nine months period ended December 31, 2025, the company demonstrated strong growth momentum across all key financial parameters.

Segment-wise Performance

The company operates through two primary segments - Pharmaceuticals and Chemicals. For Q3 FY26, the pharmaceutical segment generated revenue of ₹356.05 crore compared to ₹300.58 crore in Q3 FY25, while the chemical segment recorded ₹287.82 crore against ₹275.14 crore in the corresponding previous quarter.

Interim Dividend Declaration

The Board of Directors declared an interim dividend of ₹1 per equity share (50%) having face value of ₹2 each for the financial year 2025-26. The company has fixed February 17, 2026 as the record date to determine eligible shareholders for the interim dividend payment.

Exceptional Items and Corporate Developments

The company reported exceptional items worth ₹11.21 crore in Q3 FY26, primarily arising from changes in wage definition following the notification of four Labour Codes by the Government of India on November 21, 2025. During the quarter, the Board approved the closure of IOL Life Sciences Limited, a wholly owned subsidiary, through striking off from the Register of Companies. Additionally, the company incorporated IOL Pharmaxis UK Limited in the United Kingdom on October 16, 2025, though business operations have not yet commenced.

Auditor Certification

The financial results received an unmodified review report from statutory auditors Ashwani & Associates, Chartered Accountants. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI listing regulations. The company confirmed that both standalone and consolidated results are available on its website at www.iolcp.com .

IOL Chemicals & Pharmaceuticals Limited has initiated the process to strike off its wholly owned subsidiary IOL Life Sciences Limited from the register of companies. The company filed the application with the Registrar of Companies on January 27, 2026, under Section 248 of the Companies Act, 2013, as disclosed in its regulatory filing to the stock exchanges.

Strike-off Application Details

The application for striking off IOL Life Sciences Limited has been submitted pursuant to Section 248 of the Companies Act, 2013, read with applicable rules. The strike-off process is subject to receipt of necessary approvals from the Ministry of Corporate Affairs, Registrar of Companies, and other statutory authorities as applicable.

Financial Position of Subsidiary

IOL Life Sciences Limited had minimal financial contribution to the parent company's operations. The subsidiary's financial position as on March 31, 2025, reflects its dormant status:

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular SEBI/HO/CFD/-PoD-1/P/CIR/2023/123 dated July 13, 2023. The company has provided all required details in compliance with regulatory requirements.

Transaction Classification

The strike-off application does not involve any sale or disposal transaction, as clarified in the regulatory filing. Key aspects of the process include:

• No agreement for sale has been entered into
• No consideration is being received from the strike-off
• The transaction does not fall within related party transactions
• No buyers are involved in the process

The strike-off represents a corporate restructuring move to eliminate a dormant subsidiary that has not contributed to the company's operations or financial performance. IOL Chemicals and Pharmaceuticals Limited continues to focus on its core chemical and pharmaceutical operations while streamlining its corporate structure through this subsidiary elimination process.